{"id":326122,"date":"2022-04-09T01:00:00","date_gmt":"2022-04-08T23:00:00","guid":{"rendered":"https:\/\/medizinonline.com\/5-year-data-on-ixekizumab-patients-benefit-over-the-long-term\/"},"modified":"2022-04-09T01:00:00","modified_gmt":"2022-04-08T23:00:00","slug":"5-year-data-on-ixekizumab-patients-benefit-over-the-long-term","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/en\/5-year-data-on-ixekizumab-patients-benefit-over-the-long-term\/","title":{"rendered":"5-Year Data on Ixekizumab: Patients Benefit Over the Long Term"},"content":{"rendered":"

Continuous therapy with the anti-IL17 antibody ixekizumab has shown sustained long-term improvements in itch, skin pain, and health-related quality of life in patients with moderate to severe plaque psoriasis. Patients were also shown to benefit in terms of work-related productivity. This is from an analysis of data from the extension phases of the UNCOVER-1 and -2 trials with a follow-up phase through week 264.<\/strong><\/p>\n

<\/p>\n

Participants included in UNCOVER-1- and -2 were adult patients with moderate-to-severe psoriasis (BSA \u226510, sPGA \u22653, PASI \u226512) who were eligible for systemic therapy. In UNCOVER-1 (n=1296), study participants were randomized 1:1:1 to ixekizumab 80 mg every 2 weeks (q2w), ixekizumab 80 mg every 4 weeks (q4w), or placebo. In the UNCOVER-2 trial, participants (n=1224) were randomized 2:2:2:1 to ixekizumab q2w, ixekizumab q4w, etanercept 50 mg 2\u00d7 weekly, or placebo. In both studies, patients treated with ixekizumab received an initial loading dose of 160 mg.<\/p>\n

Included in the present analysis of long-term data were participants in the UNCOVER-1 and -2 trials who were randomized to ixekizumab every 2 weeks and received ixekizumab at intervals of 4 weeks during the maintenance phase (weeks 12-60) [1]. Another criterion was that a physician global assessment (PGA) score of 0 or 1 was achieved at week 12 and study participation continued until week 60 with inclusion in the subsequent extension phase. Patient characteristics and disease features of the long-term extension phase study population were comparable to the overall study population [2,3].<\/p>\n

Improvements in various patient-reported outcomes (PROs).<\/h2>\n

Patient-reported outcomes (PROs) are subjective assessments of health-related aspects as an adjunct to standard clinical measures assessed by physicians. Patient-reported outcomes included in the present analysis were the numerical rating scale for pruritus (NRS-itch), skin pain VAS (visual anaolgic scale), and the dermatological quality of life index DLQI (score of 0 or 1). Also collected were mean change in the SF-36 (“Short Form health survey”) and in the physical and mental components of this health questionnaire (PCS and MCS, respectively).<\/p>\n

 <\/p>\n

\"\"<\/p>\n

 <\/p>\n

Psoriasis-related appearance distress was operationalized by the PSAB (“Psoriasis Skin Appearance Bothersomeness”), and the WPAI (“Productivity and Activity Impairment Questionnaire”) was used as a measurement tool to capture subjectively perceived impairment in work-related productivity.<\/p>\n

At week 264, in UNCOVER-1 and -2, a proportion of 82.4% and 93.1%, respectively, achieved a reduction in NRS itch \u22654 points (Fig. 1),<\/span> an NRS score of 0 was exhibited by 51.7% and 58.5%, respectively, and the proportion of those with VAS skin pain of 0 was 59.3% and 63.1%, respectively. Regarding DLQI 0 or 1, the corresponding rates were 75.0% and 88.1%, respectively (Fig. 1)<\/span>. Changes from baseline to week 264 in other parameters were as follows: SF-36 MCS: 3.4 and 6.5, respectively; SF-36 PCS: 4.4 and 4.8, respectively; PSAB-21.3 and -22.0, respectively. There were improvements in item scores in WPAI psoriasis since baseline in both UNCOVER-1 and -2.<\/p>\n

 <\/p>\n

\"\"<\/p>\n

 <\/p>\n

In summary, 264 weeks of treatment with ixekizumab resulted in sustained improvement in several PROs, including pruritus NRS and DLQI, in both the UNCOVER-1 and UNCOVER-2 trials.<\/p>\n

\nSource: Eli Lilly<\/em><\/p>\n

 <\/p>\n

Literature:<\/p>\n

    \n
  1. Gooderham MJ, et al: Effect of Ixekizumab on Patient Reported Outcomes and Quality of Life in Patients With Moderate-to-Severe Plaque Psoriasis: 5-Year Results from the UNCOVER-1 and -2 Studies. J Drugs Dermatol 2021; 20(4): 394-401.<\/li>\n
  2. Gordon KB, et al: Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. New Engl J Med 2016; 375: 345-356.<\/li>\n
  3. Gordon KB, Colombel JF, Hardin DS. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. New Engl J Med 2016; 375: 2102.<\/li>\n<\/ol>\n

     <\/p>\n

    DERMATOLOGIE PRAXIS 2022; 32(1): 30-31<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"

    Continuous therapy with the anti-IL17 antibody ixekizumab has shown sustained long-term improvements in itch, skin pain, and health-related quality of life in patients with moderate to severe plaque psoriasis. Patients…<\/p>\n","protected":false},"author":7,"featured_media":116695,"comment_status":"closed","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":"","cat_1_feature_home_top":false,"cat_2_editor_pick":false,"csco_eyebrow_text":"Plaque psoriasis","footnotes":""},"category":[11340,11508,11530,11480,11548,11503],"tags":[12548,14032],"powerkit_post_featured":[],"class_list":["post-326122","post","type-post","status-publish","format-standard","has-post-thumbnail","category-dermatology-and-venereology","category-education","category-market-medicine","category-rheumatology","category-rx-en","category-studies","tag-ixekizumab-en","tag-psoriasis-en-2","pmpro-has-access"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-05-07 12:09:56","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"wpml_current_locale":"en_US","wpml_translations":{"fr_FR":{"locale":"fr_FR","id":326131,"slug":"donnees-a-5-ans-sur-lixekizumab-les-patients-en-beneficient-durablement","post_title":"Donn\u00e9es \u00e0 5 ans sur l'ixekizumab : les patients en b\u00e9n\u00e9ficient durablement","href":"https:\/\/medizinonline.com\/fr\/donnees-a-5-ans-sur-lixekizumab-les-patients-en-beneficient-durablement\/"},"it_IT":{"locale":"it_IT","id":326138,"slug":"dati-a-5-anni-su-ixekizumab-i-pazienti-beneficiano-a-lungo-termine","post_title":"Dati a 5 anni su ixekizumab: i pazienti beneficiano a lungo termine","href":"https:\/\/medizinonline.com\/it\/dati-a-5-anni-su-ixekizumab-i-pazienti-beneficiano-a-lungo-termine\/"},"pt_PT":{"locale":"pt_PT","id":326145,"slug":"dados-de-5-anos-sobre-ixekizumab-os-pacientes-beneficiam-a-longo-prazo","post_title":"Dados de 5 anos sobre ixekizumab: os pacientes beneficiam a longo prazo","href":"https:\/\/medizinonline.com\/pt-pt\/dados-de-5-anos-sobre-ixekizumab-os-pacientes-beneficiam-a-longo-prazo\/"},"es_ES":{"locale":"es_ES","id":326152,"slug":"datos-a-5-anos-sobre-el-ixekizumab-los-pacientes-se-benefician-a-largo-plazo","post_title":"Datos a 5 a\u00f1os sobre el ixekizumab: los pacientes se benefician a largo plazo","href":"https:\/\/medizinonline.com\/es\/datos-a-5-anos-sobre-el-ixekizumab-los-pacientes-se-benefician-a-largo-plazo\/"}},"_links":{"self":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts\/326122","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/comments?post=326122"}],"version-history":[{"count":0,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts\/326122\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/media\/116695"}],"wp:attachment":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/media?parent=326122"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/category?post=326122"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/tags?post=326122"},{"taxonomy":"powerkit_post_featured","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/powerkit_post_featured?post=326122"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}